Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Next Previous
Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck Biopharma

Most Recent Events

  • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 17 Mar 2023 Results (n=83 expansion cohort of NCT02517398 patients with non-small cell lung cancer) assessing efficacy and safety of Bintrafusp Alfa in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors published in the Oncologist
  • 08 Feb 2023 Results(As of May 15, 2020, n=32 ; from an expansion cohort of a phase I study) assessing efficacy of Bintrafusp Alfa in Patients with Pretreated Colorectal Cancer published in the Oncologist

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top